Export 39 results:
Author Title [ Type(Asc)] Year
Filters: Author is Hill, Heather  [Clear All Filters]
Journal Article
R. Salerno-Gonçalves, Chen, W. H., Mulligan, M. J., Frey, S. E., Stapleton, J. T., Keitel, W. A., Bailey, J., Sendra, E., Hill, H., Johnson, R. A., and Sztein, M. B., “Vaccine-related major cutaneous reaction size correlates with cellular-mediated immune responses after tularaemia immunisation.”, Clin Transl Immunology, vol. 10, no. 1, p. e1239, 2021.
M. J. Mulligan, Stapleton, J. T., Keitel, W. A., Frey, S. E., Chen, W. H., Rouphael, N., Edupuganti, S., Beck, A., Winokur, P. L., Sahly, H. M. El, Patel, S. M., Atmar, R. L., Graham, I., Anderson, E., El-Kamary, S. S., Pasetti, M. F., Sztein, M. B., Hill, H., and Goll, J. B., “Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.”, Vaccine, vol. 35, no. 36, pp. 4730-4737, 2017.
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
M. J. Mulligan, Bernstein, D. I., Winokur, P., Rupp, R., Anderson, E., Rouphael, N., Dickey, M., Stapleton, J. T., Edupuganti, S., Spearman, P., Ince, D., Noah, D. L., Hill, H., and Bellamy, A. R., “Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
S. R. Walsh, Wilck, M. B., Dominguez, D. J., Zablowsky, E., Bajimaya, S., Gagne, L. S., Verrill, K. A., Kleinjan, J. A., Patel, A., Zhang, Y., Hill, H., Acharyya, A., Fisher, D. C., Antin, J. H., Seaman, M. S., Dolin, R., and Baden, L. R., “Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.”, J Infect Dis, vol. 207, no. 12, pp. 1888-97, 2013.
R. B. Belshe, Frey, S. E., Graham, I., Mulligan, M. J., Edupuganti, S., Jackson, L. A., Wald, A., Poland, G., Jacobson, R., Keyserling, H. L., Spearman, P., Hill, H., and Wolff, M., “Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”, J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
S. E. Frey, Houghton, M., Coates, S., Abrignani, S., Chien, D., Rosa, D., Pileri, P., Ray, R., Di Bisceglie, A. M., Rinella, P., Hill, H., Wolff, M. C., Schultze, V., Han, J. H., Scharschmidt, B., and Belshe, R. B., “Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.”, Vaccine, vol. 28, no. 38, pp. 6367-73, 2010.
N. B. Halasa, Gerber, M. A., Berry, A. A., Anderson, E. L., Winokur, P., Keyserling, H., Eckard, A. Ross, Hill, H., Wolff, M. C., McNeal, M. M., Edwards, K. M., and Bernstein, D. I., “Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.”, J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.
W. A. Keitel, Campbell, J. D., Treanor, J. J., Walter, E. B., Patel, S. M., He, F., Noah, D. L., and Hill, H., “Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.”, J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
R. C. Brady, Treanor, J. J., Atmar, R. L., Keitel, W. A., Edelman, R., Chen, W. H., Winokur, P., Belshe, R., Graham, I. L., Noah, D. Lee, Guo, K., and Hill, H., “Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.”, Vaccine, vol. 27, no. 37, pp. 5091-5, 2009.
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., “Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
S. E. Frey, Bernstein, D. I., Gerber, M. A., Keyserling, H. L., Munoz, F. M., Winokur, P. L., Turley, C. B., Rupp, R. E., Hill, H., Wolff, M., Noah, D. L., Ross, A. C., Cress, G., and Belshe, R. B., “Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, J Infect Dis, vol. 206, no. 6, pp. 828-37, 2012.
T. L. Jensen, Frasketi, M., Conway, K., Villarroel, L., Hill, H., Krampis, K., and Goll, J. B., “RSEQREP: RNA-Seq Reports, an open-source cloud-enabled framework for reproducible RNA-Seq data processing, analysis, and result reporting.”, F1000Res, vol. 6, p. 2162, 2017.
D. L. Noah, Hill, H., Hines, D., E White, L., and Wolff, M. C., “Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.”, Clin Vaccine Immunol, vol. 16, no. 4, pp. 558-66, 2009.
A. C. Galassie, Goll, J. B., Samir, P., Jensen, T. L., Hoek, K. L., Howard, L. M., Allos, T. M., Niu, X., Gordy, L. E., C Creech, B., Hill, H., Joyce, S., Edwards, K. M., and Link, A. J., “Proteomics show antigen presentation processes in human immune cells after AS03-H5N1 vaccination.”, Proteomics, vol. 17, no. 12, 2017.
D. F. Hoft, Lottenbach, K., Goll, J. B., Hill, H., Winokur, P. L., Patel, S. M., Brady, R. C., Chen, W. H., Edwards, K., C Creech, B., Frey, S. E., Blevins, T. P., Salomon, R., and Belshe, R. B., “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.”, J Infect Dis, vol. 214, no. 7, pp. 1020-9, 2016.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., “Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
S. E. Frey, Bernstein, D. I., Brady, R. C., Keitel, W. A., Sahly, H. El, Rouphael, N. Georges, Mulligan, M. J., Atmar, R. L., Edupuganti, S., Patel, S. M., Dickey, M., Graham, I., Anderson, E. L., Noah, D. L., Hill, H., Wolff, M., and Belshe, R. B., “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
S. E. Frey, Winokur, P. L., Hill, H., Goll, J. B., Chaplin, P., and Belshe, R. B., “Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.”, Vaccine, vol. 32, no. 23, pp. 2732-9, 2014.
S. L. Hillier, Ferrieri, P., Edwards, M. S., Ewell, M., Ferris, D., Fine, P., Carey, V., Meyn, L., Hoagland, D., Kasper, D. L., Paoletti, L. C., Hill, H., and Baker, C. J., “A Phase 2, Randomized, Control Trial of Group B Streptococcus (GBS) Type III Capsular Polysaccharide-tetanus Toxoid (GBS III-TT) Vaccine to Prevent Vaginal Colonization With GBS III.”, Clin Infect Dis, vol. 68, no. 12, pp. 2079-2086, 2019.
G. J. Gorse, Grimes, S., Buck, H., Mulla, H., White, P., Hill, H., May, J., Frey, S. E., and Blackburn, P., “A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.”, Vaccine, vol. 40, no. 9, pp. 1271-1281, 2022.
G. J. Gorse, Grimes, S., Buck, H., Mulla, H., White, P., Hill, H., May, J., Frey, S. E., and Blackburn, P., “MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.”, Vaccine, vol. 40, no. 10, pp. 1472-1482, 2022.
R. B. Belshe, Frey, S. E., Graham, I. L., Anderson, E. L., Jackson, L. A., Spearman, P., Edupuganti, S., Mulligan, M. J., Rouphael, N., Winokur, P., Dolor, R. J., Woods, C. W., Walter, E. B., Chen, W. H., Turley, C., Edwards, K. M., C Creech, B., Hill, H., and Bellamy, A. R., “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
L. A. Jackson, Chen, W. H., Stapleton, J. T., Dekker, C. L., Wald, A., Brady, R. C., Edupuganti, S., Winokur, P., Mulligan, M. J., Keyserling, H. L., Kotloff, K. L., Rouphael, N., Noah, D. L., Hill, H., and Wolff, M. C., “Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.”, J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
D. I. Bernstein, Jackson, L., Patel, S. M., Sahly, H. M. El, Spearman, P., Rouphael, N., Rudge, T. L., Hill, H., and Goll, J. B., “Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.”, Vaccine, vol. 32, no. 47, pp. 6284-93, 2014.